Streptococcus mutans Surface α-Enolase Binds Salivary Mucin MG2 and Human Plasminogen

Jingping Ge,† Diana M. Catt,‡ and Richard L. Gregory†,*

Department of Pathology and Laboratory Medicine, School of Medicine,† and Department of Oral Biology, School of Dentistry,‡ Indiana University, Indianapolis, Indiana

Received 24 February 2004/Returned for modification 31 March 2004/Accepted 28 July 2004

Matrix-assisted laser desorption ionization–time of flight mass spectrometry analysis identified enolase as a cell surface component of Streptococcus mutans, which was confirmed by enzyme-linked immunosorbent assay, Western blotting, and transmission electron microscopy. Surface enolase was demonstrated to bind to human plasminogen and salivary mucin MG2. The results suggested a role for enolase in S. mutans attachment, clearance, or breach of the bloodstream barrier.

Streptococcus mutans is an alpha-hemolytic and nongroupable streptococcus, which causes dental caries and occasionally bacterial endocarditis (BE) (20). Some surface proteins of S. mutans are virulence factors with functions critical to viability, such as adhesion (2). Adhesion is one of the most important steps in the pathogenicity of microorganisms, and bacterial cell surface-mediated interactions with salivary proteins may be the first step in S. mutans attachment to a tooth surface coated with salivary pellicle or saliva-coated plaque (11). Liu et al. reported that S. mutans binds to salivary mucins, but the specific molecule responsible for this binding was unknown (18). Salivary mucin MG2 is a 180-kDa glycoprotein (22). Mucin MG2 binds to several oral microbes, including S. mutans, Actinobacillus actinomycetemcomitans, and Candida albicans, and forms heterotypic complexes with salivary proteins, including secretory immunoglobulin A (SIgA) and lactoferrin (4, 15, 18, 19, 29).

Enolase is a 47-kDa cytoplasmic enzyme in the glycolytic pathway (21). There are three distinct isoforms (α, β, and γ) of enolase, each with the same molecular mass. α-Enolase is the isoform typically found in bacteria. Surface α-enolase has been recently identified on Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus oralis, and A. actinomycetemcomitans (3, 13, 16, 25, 32). Surface enolase of S. pyogenes binds and activates human plasminogen, a molecule which plays a crucial role in fibrinolysis, homeostasis, and the degradation of extracellular matrix (8). Proteins, such as enolase, with exposed carboxyl-terminal lysines on the cell surface can bind and promote plasminogen activation (33).

In the present study, we identified α-enolase from a cell surface protein preparation of S. mutans A32-2 by two-dimensional polyacrylamide gel electrophoresis (PAGE) and matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) analysis. The results of enzyme-linked immunosorbent assay (ELISA), Western blot, and transmission electron microscopy (TEM) confirmed α-enolase on the cell surface as well as in the cytoplasm of S. mutans. Results of Western blot, TEM, and ELISA experiments demonstrate that S. mutans surface enolase binds to human plasminogen and human salivary mucin MG2.

S. mutans A32-2 was isolated from a highly-caries-active patient and expresses significantly more surface proteins than isolates from caries-free subjects (26). Surface protein, cell wall, and cytoplasmic samples were purified according to methods described previously (17, 24, 26). Briefly, S. mutans was harvested, washed in surface protein buffer (10 mM phosphate-buffered saline, 1 mM CaCl2, pH 7.2, 1% phenylmethylsulfonyl fluoride), and sheared in a Waring blender for three 1-min cycles at high speed. The unbroken cells and debris were removed by centrifugation at 10,000 × g for 10 min at 4°C. The supernatant containing surface proteins was centrifuged at 16,000 × g for 15 min at 4°C, transferred to a fresh tube, and centrifuged again at 110,000 × g for 2.5 h at 4°C. The pellet containing the surface proteins was resuspended in surface protein buffer and stored at −80°C. Cytoplasmic and cell wall fractions were collected from disrupted cells by a sucrose gradient. Protein concentrations of all preparations were measured by a QuantiPro bicinchoninic acid assay kit (Sigma).

S. mutans subcellular samples or saliva components were separated by sodium dodecyl sulfate (SDS)-PAGE (7.5% polyacrylamide). MALDI-TOF MS was performed on trypsin-digested, Coomassie stained spots excised from surface proteins separated on two-dimensional PAGE gels (32) at the Biochemistry Biotechnology Facility (Dept. of Biochemistry, Indiana University School of Medicine). About 160 spots from the gel were visualized by computer-generated imaging, and 96 spots were analyzed by MALDI-TOF MS with Profound software (34) (http://129.85.19.192/profound_bin/WebProFound.exe), based on Z value and coverage percentage (data not shown). Two spots with molecular masses of 47 and 60 kDa and pIs of pIs 4.7 and 6.0, respectively, were identified as enolase. Enolase is predicted to be encoded by a single-copy gene designated SMU.1247 (1). Around 67% of the smaller enolase peptide mass matched the computed enolase mass using the top 50 MALDI-TOF peptides, and the Z value was 2.36. Around 38% of the larger measured enolase peptide mass matched the computed enolase mass using the top 50 MALDI-TOF peptides, and the Z value was 1.65. Modification of each protein was also predicted based on the MALDI-TOF

* Corresponding author. Mailing address: Department of Oral Biology, Indiana University School of Dentistry, 1121 West Michigan St., Indianapolis, IN 46202. Phone: (317) 274-9949. Fax: (317) 278-1411. E-mail: rgregory@iupui.edu.
The enolase peptide $^{57}$SRYGGLGTLQ$^{66}$ was predicted to be phosphorylated in both spots, and the computed mass for the phosphorylated peptide was 1,305.456, while the measured mass was 1,304.812. Serine, threonine, or tyrosine in this peptide may be potentially phosphorylated. The peptides $^{11}$EVLD$^{16}$R, $^{42}$SFYNLK$^{48}$, and $^{30}$TGSLR$^{36}$ may also be potentially phosphorylated in the larger spot. Posttranslational modification may alter the binding properties of enolase as well as the molecular weight. Our analysis of the predicted protein sequence of enolase of S. mutans reveals that this protein lacks the hexameric motif (LPXTGX) typical for anchoring proteins of gram-positive bacteria to the cell wall (9). It is not yet understood how enolase is transported to and attaches to the surface of the bacterium (23).

Human enolase can be posttranslationally acylated or phosphorylated in vivo and in vitro (5, 7). Our analysis of the enolase protein sequence of S. mutans suggests the possibility of phosphorylation sites based on the MALDI-TOF data. Phosphorylation can affect protein-protein interactions (6), and phosphorylated enolase may bind to the receptor on the cell surface.

Bacterial samples for immunogold bead staining were prepared for TEM (http://www.nanoprobes.com/Inf2016.html) to study the presence of surface enolase on S. mutans and its binding ability to human plasminogen. The presence of gold beads at the outer edge of S. mutans cells demonstrated anti-$\alpha$-enolase antibody (1:200; Laboratory of Bacterial Pathogenesis and Immunology, Rockefeller University, New York, N.Y.) reacting with a protein on the cell wall of S. mutans (results not shown). Control cells without anti-$\alpha$-enolase antibody did not stain. These results supported the MALDI-TOF finding of enolase on the surface of S. mutans. Incubation of S. mutans with human plasminogen (0.02 mg/ml; ICN Biomedicals, Aurora, Ohio) followed by incubation with goat anti-plasminogen antibody (1:200; ICN) and anti-goat antibody conjugated to gold beads (1:200; Nanoprobes, Yaphank, N.Y.) demonstrated the ability of human plasminogen to bind to the surface of S. mutans. Control cells without human plasminogen did not stain. The results suggested that S. mutans surface proteins bound to human plasminogen.

Far-Western blot analysis (14) was used to study the binding ability of enolase to human plasminogen and mucin MG2. Enolase in the cell surface, cell wall, and cytoplasmic samples reacted with anti-$\alpha$-enolase antibody (1:300) in Western blots (Fig. 1A). Enolase (47 kDa) in the cell surface, cell wall, and cytoplasmic fractions binds plasminogen (0.02 mg/ml; Sigma). Mucin MG2 in the complex was glycosylated protein (results not shown), and the Western blots of salivary proteins incubated with anti-mucin MG2 antibody (1:1,000; Laboratory of Biochemistry, Boston University) demonstrated that the 180-kDa protein was mucin MG2 (Fig. 2A). Schiff’s staining of the salivary proteins indicated the 180-kDa protein was a highly glycosylated protein (results not shown), and the Western blots of salivary proteins incubated with anti-mucin MG2 antibody (1:1,000; Laboratory of Biochemistry, Boston University) demonstrated that the 180-kDa protein was mucin MG2 (Fig. 2A). Separated subcellular proteins, when incubated with salivary supernatant (containing mucins MG1 and MG2) followed by incubation with anti-mucin MG2 antibody, confirmed enolase in subcellular samples binding to salivary mucin MG2 (Fig. 2B). Negative controls were not incubated with saliva supernatant or anti-mucin MG2 antibody, and there was no band in the negative controls. The interaction was confirmed by coinmoprecipitation (results not shown). The complex, formed by mixing the S. mutans subcellular samples with salivary proteins, was purified with anti-$\gamma$-enolase antibody (1:200) and protein A (10 μg; Sigma). Mucin MG2 in the complex was confirmed with anti-mucin MG2 antibody (1:1,000) in Western blot analysis.

ELISA was used to assess enolase localization and the ability of enolase to bind human plasminogen and mucins MG1 and MG2. ELISA confirmed that not only was enolase present in the cytoplasmic fraction as expected, it was also observed in the cell surface fraction (Fig. 3). As expected, $\alpha$-enolase reacted...
with anti-α-enolase (1:500) and anti-γ-enolase antibodies (1:500; Sigma), while the no-antibody negative controls did not. The data were analyzed by Student’s t test. The version for independent samples was used. The variances in the groups were assumed to be equal, and the test was two sided. The P values of all groups were <0.05, which means there are significant differences between experimental groups and control groups. The presence of enolase in the culture supernatant suggested either an active secretion of enolase or the presence of lysed bacterial cells. ELISA plates were coated with rabbit anti-enolase antibody (1:500), which bound enolase in surface, cell wall, and cytoplasm samples. Enolase subsequently reacted with human plasminogen (0.02 mg/ml), which was detected by incubation with goat anti-plasminogen antibody (1:1,000), and anti-goat IgG conjugated with peroxidase (1:1,000). In a similar experiment, proteins in the subcellular samples able to bind to human salivary mucins MG1 and MG2 were detected by ELISA. An ELISA plate was coated with subcellular samples (surface protein, cell wall, and cytoplasm samples), incubated sequentially with saliva supernatant (containing salivary mucins MG1 and MG2), rabbit anti-mucin MG1 antibody (1:1,000) or anti-mucin MG2 antibodies (1:1,000), and anti-rabbit IgG conjugated with peroxidase (1:1,000). Following color development, the absorbance of each well was measured at 490 nm. The data were analyzed by Student’s t test (independent samples with equal variances and two sides), and the P values of all groups were <0.05.
carboxyl-terminal lysines on the streptococcal cell surface can promote plasminogen activation. *S. pyogenes* surface enolase binds to the Kringle region of plasminogen, promotes plasminogen activation, and protects plasmin from its inhibitor, α₂ antiplasmin (27, 33). Preliminary analysis of the *S. mutans* enolase amino acid sequence reveals two C-terminal lysines, which bind to plasminogen (our laboratory’s unpublished data). Surface enolase may help *S. mutans* disseminate through oral tissues to enter the bloodstream, where *S. mutans* may cause BE (12). The reported range of cases of BE caused by *S. mutans* is 1.7 to 4.8%. This may be greatly underreported, however, due to *S. mutans* present in the less-specific diagnosis of BE due to viridans group streptococcal (48% of all BE cases) infections (30). Enolase may serve to potentiate pathophysiological processes.

Further studies will be needed to define the role of enolase in interactions with the human salivary component mucin MG2. Binding of surface enolase to human plasminogen may either lead to bacterial attachment to oral tissues or salivary proteins. The interaction of surface enolase with mucin MG2 may serve as a bridge between *S. mutans* and its an-chor-in-actinomyces streptococcus binding protein on the surface of pathogenic streptococci. J. Biol. Chem. 272:1712–1721.


REFERENCES


